Evidence map›Paper›PMID 34312316›Full record

Trial reportThorax2022

A telerehabilitation programme in post-discharge COVID-19 patients (TERECO): a randomised controlled trial.

Jian'an Li, Wenguang Xia, Chao Zhan, Shouguo Liu, Zhifei Yin, Jiayue Wang, Yufei Chong, Chanjuan Zheng, Xiaoming Fang, Wei Cheng and 1 more

Registry-linked trialAbstract readRandomized Controlled TrialEquivalence Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Thorax, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05532904 (Evaluation and Comparison of Multidisciplinary Day-hospital Versus Waiting List Management of Persistent Symptoms After an Acute Episode of COVID-19), which is not on this map. Cited by 137 papers, 28 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 28 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05532904 nacompletednot on this mapstarted 2023, after this paper: background citation

Evaluation and Comparison of Multidisciplinary Day-hospital Versus Waiting List Management of Persistent Symptoms After an Acute Episode of COVID-19

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2023 to 2025Enrolled80ConditionsPost COVID-19 ConditionArmsPersonalized multidisciplinary day-hospital intervention
3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 28 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Guideline
  12. Rehabilitation and COVID-19: systematic review by Cochrane Rehabilitation.European journal of physical and rehabilitation medicine · 2023
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Non-Pharmacological Therapies for Post-Viral Syndromes, Including Long COVID: A Systematic Review.International journal of environmental research and public health · 2023
    Pooled it
  17. Prevalence, risk factors and treatments for post-COVID-19 breathlessness: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2022
    Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Jian'an Li *Center for Rehabilitation Medicine, Jiangsu Province Hospital/Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, People's Republic of China.
Wenguang Xia *Department of Rehabilitation Medicine, Hubei Province Hospital of Integrated Chinese and Western Medicine, Wuhan, Hubei, People's Republic of China.
Chao Zhan *Department of Rehabilitation Medicine, Huangshi Traditional Chinese Medicine Hospital, Huangshi, Hubei, People's Republic of China.
Shouguo Liu *Center for Rehabilitation Medicine, Jiangsu Province Hospital/Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, People's Republic of China.
Zhifei YinCenter for Rehabilitation Medicine, Jiangsu Province Hospital/Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, People's Republic of China.
Jiayue WangCenter for Rehabilitation Medicine, Jiangsu Province Hospital/Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, People's Republic of China.
Yufei ChongDepartment of Rehabilitation Medicine, Hubei Province Hospital of Integrated Chinese and Western Medicine, Wuhan, Hubei, People's Republic of China.
Chanjuan ZhengDepartment of Rehabilitation Medicine, Hubei Province Hospital of Integrated Chinese and Western Medicine, Wuhan, Hubei, People's Republic of China.
Xiaoming FangDepartment of Rehabilitation Medicine, Huangshi Traditional Chinese Medicine Hospital, Huangshi, Hubei, People's Republic of China.
Wei ChengDepartment of Rehabilitation Medicine, Huangshi Traditional Chinese Medicine Hospital, Huangshi, Hubei, People's Republic of China.
Jan D ReinhardtInstitute for Disaster Management and Reconstruction, Sichuan University, Chengdu, Sichuan, People's Republic of China jan.reinhardt@paraplegie.ch.ORCID 0000-0001-7250-6906

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate superiority of a telerehabilitation programme for COVID-19 (TERECO) over no rehabilitation with regard to exercise capacity, lower limb muscle strength (LMS), pulmonary function, health-related quality of life (HRQOL) and dyspnoea.

designParallel-group randomised controlled trial with 1:1 block randomisation.

settingThree major hospitals from Jiangsu and Hubei provinces, China.

participants120 formerly hospitalised COVID-19 survivors with remaining dyspnoea complaints were randomised with 61 allocated to control and 59 to TERECO.

interventionUnsupervised home-based 6-week exercise programme comprising breathing control and thoracic expansion, aerobic exercise and LMS exercise, delivered via smartphone, and remotely monitored with heart rate telemetry. OUTCOMES: Primary outcome was 6 min walking distance (6MWD) in metres. Secondary outcomes were squat time in seconds; pulmonary function assessed by spirometry; HRQOL measured with Short Form Health Survey-12 (SF-12) and mMRC-dyspnoea. Outcomes were assessed at 6 weeks (post-treatment) and 28 weeks (follow-up).

resultsAdjusted between-group difference in change in 6MWD was 65.45 m (95% CI 43.8 to 87.1; p<0.001) at post-treatment and 68.62 m (95% CI 46.39 to 90.85; p<0.001) at follow-up. Treatment effects for LMS were 20.12 s (95% CI 12.34 to 27.9; p<0.001) post-treatment and 22.23 s (95% CI 14.24 to 30.21; p<0.001) at follow-up. No group differences were found for lung function except post-treatment maximum voluntary ventilation. Increase in SF-12 physical component was greater in the TERECO group with treatment effects estimated as 3.79 (95% CI 1.24 to 6.35; p=0.004) at post-treatment and 2.69 (95% CI 0.06 to 5.32; p=0.045) at follow-up.

conclusionsThis trial demonstrated superiority of TERECO over no rehabilitation for 6MWD, LMS, and physical HRQOL. TRIAL REGISTRATION NUMBER: ChiCTR2000031834.

Indexed as

COVID-19TelerehabilitationAftercareDyspneaHumansPatient DischargeQuality of LifeCOVID-19pulmonary rehabilitation

Identifiers

PMID34312316
PMCPMC8318721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.